Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us
Conference Highlights
American Society of Hematology (ASH)
ASH 2019 – Multiple Myeloma: Wrap-Up
ASH 2019 – Multiple Myeloma: Wrap-Up
New 4-Drug Combo Leads to Promising Responses in Multiple Myeloma
ASH 2019 – Multiple Myeloma: Wrap-Up
Patients with “challenging-to-treat” relapsed multiple myeloma showed promising responses to a new 4-drug combination, one of the first of its kind to be used in multiple myeloma.
Read More ›
A New Treatment Option for Relapsed/Refractory Multiple Myeloma
ASH 2019 – Multiple Myeloma: Wrap-Up
Now that patients with multiple myeloma are living longer, researchers are focusing more on patients’ quality of life during and after cancer treatment. New research says there’s good news: 1 study found that adding an extra drug to a standard treatment made patients live longer, with no negative impact on their quality of life.
Read More ›
CAR T-Cell Therapy: A New Treatment for Myeloma?
ASH 2019 – Multiple Myeloma: Wrap-Up
CAR T-cell therapy – a type of cancer treatment that uses specially altered T-cells from the human body to attack cancer cells – could soon be used to fight multiple myeloma. CAR T-cell therapy has shown huge promise in other types of cancer but would be a new treatment for patients with this type of cancer.
Read More ›
This 3-Drug Combo Improves Survival, But Does it Lower Quality of Life? Investigators Say No
ASH 2019 – Multiple Myeloma: Wrap-Up
Exciting new research shows that adding daratumumab to a common multiple myeloma treatment slowed down cancer progression in patients who had relapsed or did not respond to other treatments.
Read More ›
Promising Results Seen with the Addition of Daratumumab to Standard of Care in Myeloma Patients Eligible for Transplant
ASH 2019 – Multiple Myeloma: Wrap-Up
In patients with newly diagnosed multiple myeloma who were fit for transplant, adding daratumumab to a commonly used treatment regimen led to impressive responses.
Read More ›
Possible New Treatment Option for Patients with Relapsed/Refractory Systemic Amyloid Light Chain Amyloidosis
ASH 2019 – Multiple Myeloma: Wrap-Up
Exciting research from the annual ASH conference showed that a new drug combination led to significant improvements in patients with systemic amyloid light chain amyloidosis. This could mean more treatment options for patients with a very limited choice of therapies.
Read More ›
Daratumumab Added to Standard Therapy = Longer Survival in Newly Diagnosed Multiple Myeloma
ASH 2019 – Multiple Myeloma: Wrap-Up
When given daratumumab along with standard-of-care treatment, patients with newly diagnosed, transplant-ineligible multiple myeloma lived longer than those who received standard of care alone.
Read More ›
New Immunotherapy Treatment Looks Promising in Relapsed/Refractory Multiple Myeloma
ASH 2019 – Multiple Myeloma: Wrap-Up
CAR T-cell therapy, a type of cancer treatment that uses specially altered T-cells from the human body to attack cancer cells, has led to exciting results in other types of cancer…could it soon be used to treat multiple myeloma?
Read More ›
Conference Correspondent Coverage is Brought to You by the Publishers of:
Learn more about our family of publications.
View Our Publications
Home
Conference Highlights
View All Conference Highlights
Year in Review / Wrap-Ups
Wrap-Ups
Year in Review
Contact Us